Related Experiment Video
Updated: Jun 26, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Cyberknife radiosurgery for trigeminal schwannomas
Gordon T Sakamoto1, D John Borchers, Furen Xiao
1Department of Neurosurgery, Stanford University Medical Center, Stanford, California 94305, USA. gsaka@stanford.edu
Neurosurgery
|January 24, 2009
Summary
CyberKnife radiosurgery achieved 100% tumor control for trigeminal schwannomas (TS). This frameless robotic system shows promising results comparable to gamma knife, with tumor volume reduction and symptom improvement in patients with TS.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Trigeminal schwannomas (TS) are benign tumors typically managed with surgical resection or stereotactic radiosurgery.
- Gamma knife is commonly used in radiosurgical series for TS treatment.
- CyberKnife is an alternative frameless, robotic stereotactic radiosurgical system.
Purpose of the Study:
- To report the initial clinical experience and outcomes of using the CyberKnife system for treating trigeminal schwannomas.
- To evaluate the efficacy and safety of CyberKnife radiosurgery for TS.
Main Methods:
- Retrospective review of 13 consecutive patients with TS treated with CyberKnife between 2003 and 2007.
- Analysis of medical records and diagnostic imaging, including tumor volume and marginal dose.
- Assessment of clinical follow-up data, including tumor control and symptom changes.
Main Results:
- 100% tumor control rate was observed in the treated patients.
- Average tumor volume reduction was 45%, with a range of 14-98%.
- Modest improvements in facial pain, numbness, and headaches were noted in some patients; adverse events included jaw weakness and asymptomatic radiation necrosis.
Conclusions:
- CyberKnife treatment for trigeminal schwannomas demonstrates comparable tumor control rates and clinical outcomes to gamma knife radiosurgery.
- Initial results are promising, but long-term follow-up studies are necessary to confirm sustained efficacy and safety.
